Pharmacological reduction of neutrophil infiltration reduces Clostridioides difficile infection severity
mBio · 2026
DOI: 10.1128/mbio.03430-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2026. Verfasst von Orlaith Keenan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections, Neutrophil Infiltration, Misoprostol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Clostridioides difficile is the leading cause of nosocomial infections and an urgent public health threat. This bacterial pathogen is challenging to treat due to antibiotic resistance and high recurrence rates, highlighting the need for additional therapeutic strategies. Host inflammatory responses are major drivers of disease severity during C. difficile infection (CDI), yet few therapeutic strategies target these pathways. Here, we show that the prostaglandin E 1 (PGE 1 ) analog misoprostol markedly reduces CDI severity by modulating host immune responses. During CDI, misoprostol decreases circulating neutrophils and limits infiltration into the colon, reducing epithelial damage, intestinal pathology, and infection severity. Additionally, misoprostol reduces serum granulocyte colony-stimulating factor (G-CSF), an important cytokine in neutrophil mobilization, controlling neutrophil levels during CDI. Together, these findings highlight neutrophil infiltration as a key driver of C. difficile- associated disease and identify innate immune modulation as a potential host-directed therapeutic strategy. IMPORTANCE Clostridioides difficile remains a leading cause of antibiotic-associated diarrhea worldwide and a major healthcare burden. While antibiotics are commonly used to treat CDI, high antibiotic resistance and recurrence rates highlight the need for additional therapeutic approaches. Here, we demonstrate that modulation of the innate immune response can mitigate disease severity. Administration of the prostaglandin analog misoprostol reduces neutrophil availability during CDI, resulting in decreased inflammation and improved outcomes. These findings suggest that fine-tuning neutrophil responses may present a promising host-directed strategy to improve CDI outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
- Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Orlaith Keenan, Gavyn Chern Wei Bee, Christopher A Hunter, Ken Cadwell, Joseph P Zackular
Förderung
- NIH HHS
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Keenan, O., Soto Ocaña, J., Semon, A., Zhou, T. H., Donohoe, K., Furth, E. E., Bee, G. C. W., Aldridge, D. L., Diamantino, J., Hunter, C. A., Cadwell, K., Aronoff, D. M., & Zackular, J. P. (2026). Pharmacological reduction of neutrophil infiltration reduces Clostridioides difficile infection severity. mBio. https://doi.org/10.1128/mbio.03430-25
Vancouver
Keenan O, Soto Ocaña J, Semon A, Zhou TH, Donohoe K, Furth EE, et al. Pharmacological reduction of neutrophil infiltration reduces Clostridioides difficile infection severity. mBio. 2026. doi:10.1128/mbio.03430-25
BibTeX
@article{Keenan2026,
author = {Keenan, Orlaith and Soto Ocaña, Joshua and Semon, Alexa and Zhou, Tiffany H and Donohoe, Kassy and Furth, Emma E and Bee, Gavyn Chern Wei and Aldridge, Daniel L and Diamantino, Juliana and Hunter, Christopher A and Cadwell, Ken and Aronoff, David M and Zackular, Joseph P},
title = {Pharmacological reduction of neutrophil infiltration reduces Clostridioides difficile infection severity},
journal = {mBio},
year = {2026},
doi = {10.1128/mbio.03430-25}
}
EUVIMED